Trial reportThe Indian journal of medical research2013
Effect of zoledronic acid on bone mineral density in patients of celiac disease: a prospective, randomized, pilot study.
Trial report in The Indian journal of medical research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Bones of contention: bone mineral density recovery in celiac disease--a systematic review.Nutrients · 2015Pooled it
- Long-term treatment with denosumab in patients with celiac disease and osteoporosis at high risk of fracture: a retrospective study.Internal and emergency medicine · 2026Article
- Vitamin D and malabsorptive gastrointestinal conditions: A bidirectional relationship?Reviews in endocrine & metabolic disorders · 2023Review
- Musculoskeletal Complications of Celiac Disease: A Case-Based Review.Mediterranean journal of rheumatology · 2023Review
- Osteoporosis and Celiac Disease: Updates and Hidden Pitfalls.Nutrients · 2023Review
- Celiac disease and bone.Archives of endocrinology and metabolism · 2022Review
- Bone Loss Correlated with Parathyroid Hormone Levels in Adult Celiac Patients.Middle East journal of digestive diseases · 2022Article
- Static and time-dependent mechanical response of organic matrix of bone.Journal of the mechanical behavior of biomedical materials · 2019Article
- A Serological Diagnosis of Coeliac Disease Is Associated with Osteoporosis in Older Australian Adults.Nutrients · 2018Article
- Extraintestinal manifestations of coeliac disease.Nature reviews. Gastroenterology & hepatology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
objectivesThe symptoms of celiac disease (CD) are varied and metabolic bone disease (MBD) is less recognized amongst all manifestations in CD patients. Bone disease in CD is attributed to secondary hyperparathyroidism, which in turn is associated with increased bone remodelling. Improvement in bone mineral density (BMD) with gluten free diet (GFD) is known, but the data on efficacy of bisphosphonates in CD patients are limited. Bisphosphonates being a potent inhibitor of bone resorption may be useful in patients with CD having low BMD. The aim of the present investigation was to study the effect of zoledronic acid on BMD in CD patients.
methodsA total of 28 CD patients were randomized to receive GFD, calcium and cholecalciferol (group A), and zoledronic acid (group B). Baseline biochemical tests and T-score by dual energy x-ray absorptiometer were done and repeated after 12 months.
resultsThe T-score showed improvement in the control arm (group A) from -3.31 ± 1.46 to -2.12 ± 1.44, a gain of 35.9 per cent (P<0.05) and in drug arm (group B) -2.82 ± 1.27 to -1.06 ± 1.84, registering a gain of 62.4 per cent (P<0.001). However, there was no difference in improvement of T-score in zoledronic acid group as compared to the control group. INTERPRETATION &
conclusionsAdministration of zoledronic acid was not found to be better than GFD alone in increasing BMD in CD patients with low BMD in this pilot study.
Indexed as
Identifiers
24521630PMC3978976W2107636516What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.